On the recordJuly 19, 2011
It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.
Source
congress.govEditor's note · Context
Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.
Share
More from Pat Toomey
Jul 11, 2022
But that does not mean that Congress should be throwing even more billions of Federal taxpayer dollars at them to build out more services for riders they do not have.
Jul 30, 2022
It's a budgetary gimmick that has the intent of making it possible to have a huge explosion in unrelated spending. This is not what this bill was about. We can fix it. We can do it immediately.
Jul 21, 2022
Among the most fundamental aspects of our republic, and a democratic system is to accept the outcome of elections.
Other voices in this conversation
